Evolus Inc Revenue Growth Rates (EOLS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Evolus Inc   (NASDAQ: EOLS)
 

EOLS's Revenue Growth by Quarter and Year

Evolus Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EOLS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 84.08
1st Quarter March 72.90
FY 156.98

EOLSs Annual Revenue
Evolus Inc 's Revenue in the fiscal year 2025 $ 297.11 millions
Evolus Inc 's Revenue in the fiscal year 2024 $ 184.30 millions
Evolus Inc 's Revenue in the fiscal year 2023 $ 202.09 millions
Evolus Inc 's Revenue in the fiscal year 2022 $ 148.62 millions
Evolus Inc 's Revenue in the fiscal year 2021 $ 99.67 millions




EOLS Revenue second quarter 2026 Y/Y Growth Comment
Evolus Inc reported Revenue improvement of 21.3% year on year in the second quarter 2026, to $ 84.08 millions, this is lower than Evolus Inc 's recent average Revenue rise of 50.72%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Revenue growth. While Evolus Inc ' s Revenue rise of 21.3% ranks overall at the positon no. 982 in the second quarter 2026.


EOLS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 15.63 % 29.43 % 39.75 %
3rd Quarter September - 12.69 % 22.13 % 47.55 %
2nd Quarter June 21.3 % 3.6 % 35.58 % 32.8 %
1st Quarter March 7.74 % 14.04 % 42.21 % 23.03 %
FY   - 11.58 % 31.76 % -

Financial Statements
Evolus Inc 's second quarter 2026 Revenue $ 84.08 millions EOLS's Income Statement
Evolus Inc 's second quarter 2025 Revenue $ 69.32 millions Quarterly EOLS's Income Statement


EOLS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 32.61 % 29.24 % 21.95 %
3rd Quarter September - -0.69 % -8.7 % 1.36 %
2nd Quarter June 15.34 % 2.45 % 12.78 % 18.29 %
1st Quarter March -20.14 % -14.3 % -2.74 % -4.42 %
FY (Year on Year)   - 11.58 % 31.76 % -


Back to EOLS Growth rate Comparisons >> Back to EOLS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #196
Overall #982

Revenue Y/Y Growth Statistics
High Average Low
237.78 % 50.72 % 3.6 %
(Mar 31 2022)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #196
Overall #982
Revenue Y/Y Growth Statistics
High Average Low
237.78 % 50.72 % 3.6 %
(Mar 31 2022)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Evolus Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
469.75 % 28.71 % -46.03 %
(Sep 30 2019)  


EOLS's II. Quarter Q/Q Revenue Comment
Evolus Inc achieved in the II. Quarter 2026 below company average Revenue jump of 15.34% quarter on quarter, to $ 84.08 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.45% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Evolus Inc 's Revenue growth quarter on quarter, overall rank is 632.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #632
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #632
Revenue Q/Q Growth Statistics
High Average Low
469.75 % 28.71 % -46.03 %
(Sep 30 2019)  


EOLS's II. Quarter Q/Q Revenue Comment
Evolus Inc achieved in the II. Quarter 2026 below company average Revenue jump of 15.34% quarter on quarter, to $ 84.08 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.45% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Evolus Inc 's Revenue growth quarter on quarter, overall rank is 632.


Evolus Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 317.11 $ 302.35 $ 297.11 $ 284.76 $ 277.01
Y / Y Revenue Growth (TTM) 14.48 % 10.11 % 11.58 % 14.67 % 16.75 %
Year on Year Revenue Growth Overall Ranking # 1012 # 172 # 76 # 198 # 151
Seqeuential Revenue Change (TTM) 4.88 % 1.76 % 4.33 % 2.8 % 0.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2538 # 2241 # 156 # 1167 # 1253


Cumulative Revenue growth Comment
Although Evolus Inc 's Annual Revenue growth year on year were below company's average 39.42% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.48% year on year, from 10.11% in Mar 31 2026.

In the Healthcare sector 193 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 172 to 1012.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 194
Overall # 1012

Revenue TTM Y/Y Growth Statistics
High Average Low
108.18 %
 39.42 %
10.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 368
S&P 500 # 2538
Cumulative Revenue growth Comment
Although Evolus Inc 's Annual Revenue growth year on year were below company's average 39.42% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.48% year on year, from 10.11% in Mar 31 2026.

In the Healthcare sector 193 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 172 to 1012.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 194
Overall # 1012

Revenue TTM Y/Y Growth Statistics
High Average Low
108.18 %
39.42 %
10.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 368
S&P 500 # 2538




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EOLS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions


About Evolus Inc Revenue Growth Rates (EOLS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Evolus Inc (CIK 1570562).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-053468
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Evolus Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.